These guidelines deal with the indications, assessment, processing, interpretation and reporting of dopamine D2 receptor SPECT and PET studies using the commercially available radiopharmaceuticals [123I]-IBZM and [123I]-epidepride, as well as [11C]-raclopride, [18F]fallypride and DMFP.